- 1. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, Mok YJ, Kim YH, Ji J, Yeh TS, Button P, Sirz?n F, Noh SH; CLASSIC trial investigators.
Lancet. 2012 Jan 28;379(9813):315-21. Epub 2012 Jan 7.
- 2. Differential effects of 5-fluorouracil on glucose transport and expressions of glucose transporter proteins in gastric cancer cells.
Won HJ, Ha TK, Kwon SJ, Cho HY, Hur SJ, Baik HH, Suh SI, Ha E, Kim YH.
Anticancer Drugs. 2010 Mar;21(3):270-6.
- 3. Expression and mutation analysis of TIG1 (tazarotene-induced gene 1) in human gastric cancer.
Son MS, Kang MJ, Park HC, Chi SG, Kim YH.
Oncol Res. 2009;17(11-12):571-80.
- 4. Nonleukemic granulocytic sarcoma presenting as intussusception of small bowel.
Lee SY, Park SJ, Kim YH, Lee JH.
Int J Clin Oncol. 2008 Oct;13(5):467-70. Epub 2008 Oct 23.
- 5. Distinct CpG island methylation profiles and BRAF mutation status in serrated and adenomatous colorectal polyps.
Kim YH, Kakar S, Cun L, Deng G, Kim YS.
Int J Cancer. 2008 Dec 1;123(11):2587-93.